Demethoxycurcumin

Demethoxycurcumin at a Glance

Demethoxycurcumin (DMC) is a curcuminoid — one of the three yellow-orange diarylheptanoid pigments of turmeric (Curcuma longa). It is the second most abundant, making up roughly 15–20% of the curcuminoid mixture, behind curcumin (~77%) and ahead of bisdemethoxycurcumin (~3%) ^{1Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →}.

Structurally, DMC is curcumin with one of its two methoxy groups removed. That small asymmetry has one consistently reported consequence: DMC is more chemically stable — and more water-soluble — than curcumin at physiological pH ^{1,6Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →Reference 6Chien MH et al. · 2020Dual targeting of the p38 MAPK-HO-1 axis and cIAP1/XIAP by demethoxycurcumin triggers caspase-mediated apoptotic cell death in oral squamous cell carcinoma cellsView study →}. Because curcumin’s poor stability and solubility are the main things that limit it in the body, DMC is often floated as the structurally more “drug-like” curcuminoid.

The honest headline is narrower than that optimism. In head-to-head laboratory assays DMC is comparable to curcumin, and in a few readouts more active (anticancer, anti-amyloid), while in others (NF-κB suppression, copper-driven antioxidant chemistry) it is slightly less active because it has one fewer methoxy group ^{2,3,5Reference 2Sandur SK et al. · 2007Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanismView study →Reference 3Ahsan H et al. · 1999Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcuminView study →Reference 5Kim DS et al. · 2001AnimalCurcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insultView study →}. As with curcumin, almost all of this is in-vitro and animal work on the isolate or the whole curcuminoid extract — there is no body of human trials on DMC by itself.

The Three Curcuminoids

Turmeric’s colour and most of its studied chemistry come from three closely related molecules that differ only in how many methoxy groups sit on their aromatic rings:

Curcuminoid	Methoxy groups	Share of the fraction
Curcumin	2	~77%
Demethoxycurcumin (DMC)	1	~15–20%
Bisdemethoxycurcumin (BDMC)	0	~3%

This ladder is the key to reading the comparative literature, because removing methoxy groups changes activity in opposite directions depending on the assay:

• NF-κB / anti-inflammatory signalling falls as methoxy groups are lost — the relative potency for suppressing TNF-induced NF-κB is curcumin > DMC > BDMC, so the methoxy groups matter here ^{2Reference 2Sandur SK et al. · 2007Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanismView study →}.
• Antiproliferative (tumour-cell growth) suppression was found to be comparable across all three, so for this readout the methoxy groups barely matter ^{2Reference 2Sandur SK et al. · 2007Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanismView study →}.
• Copper-dependent antioxidant / pro-oxidant DNA chemistry also tracks curcumin > DMC > BDMC, again favouring the more-methoxylated molecule ^{3Reference 3Ahsan H et al. · 1999Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcuminView study →}.
• Neuroprotection against beta-amyloid, strikingly, runs the other way — BDMC > DMC > curcumin — so here the fewer methoxy groups, the stronger the protection ^{5Reference 5Kim DS et al. · 2001AnimalCurcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insultView study →}.

DMC’s recurring role is the middle term: rarely the outright winner, but frequently close to curcumin and, thanks to its better stability, sometimes the more practical candidate ^{1,6Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →Reference 6Chien MH et al. · 2020Dual targeting of the p38 MAPK-HO-1 axis and cIAP1/XIAP by demethoxycurcumin triggers caspase-mediated apoptotic cell death in oral squamous cell carcinoma cellsView study →}.

What It's Used For

DMC’s activities overlap curcumin’s, and most were measured in whole-curcuminoid or isolate comparisons, not in DMC-only human studies. The value of the page is keeping the comparison honest: where DMC matches curcumin, where it beats it, and where it falls behind.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every score here rests on in-vitro/animal isolate or whole-curcuminoid data; there are no DMC-only human trials, so scores stay modest by design.

01Anticancer / antiproliferativeShaky38%Multiple tumour-cell isolate studies; growth suppression comparable to curcumin ^{2,7,8Reference 2Sandur SK et al. · 2007Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanismView study →Reference 7Lal N et al. · 2018Proteasome mediated degradation of CDC25C and Cyclin B1 in demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrestView study →Reference 8Kumar R et al. · 2018Demethoxycurcumin mediated targeting of MnSOD leading to activation of apoptotic pathway and inhibition of Akt/NF-κB survival signalling in human glioma U87 MG cellsView study →}

02Anti-inflammatory (NF-κB)Shaky32%Isolate + curcuminoid comparisons; weaker than curcumin ^{2Reference 2Sandur SK et al. · 2007Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanismView study →}

03AntioxidantShaky30%In-vitro radical/DNA assays across the three curcuminoids ^{3,4Reference 3Ahsan H et al. · 1999Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcuminView study →Reference 4Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →}

04Neuroprotection / anti-amyloidShaky28%Neuronal-cell isolate; more potent than curcumin vs Aβ ^{5Reference 5Kim DS et al. · 2001AnimalCurcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insultView study →}

Mechanisms

The load-bearing point is structural: losing one methoxy group makes DMC a weaker NF-κB/antioxidant agent than curcumin but leaves antiproliferative and anti-amyloid activity intact or enhanced — so “which curcuminoid is best” depends entirely on the endpoint.

Pharmacokinetics

DMC’s defining PK feature is the flip side of curcumin’s biggest weakness. Curcumin is notoriously unstable (it degrades rapidly at physiological/alkaline pH) and poorly water-soluble; DMC, lacking one methoxy group, is more chemically stable at physiological pH and more water-soluble ^{1,6Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →Reference 6Chien MH et al. · 2020Dual targeting of the p38 MAPK-HO-1 axis and cIAP1/XIAP by demethoxycurcumin triggers caspase-mediated apoptotic cell death in oral squamous cell carcinoma cellsView study →}. On paper that predicts better absorption and a longer systemic life, and it is the main reason DMC is proposed as a more tractable curcuminoid.

In practice the quantitative human PK of isolated DMC — oral bioavailability, Cmax, half-life — is not established. DMC reaches the body almost entirely as one component of a curcuminoid mixture (dietary turmeric or a ~95% curcuminoid extract), where it shares curcumin’s fate of extensive intestinal/hepatic glucuronidation and sulfation and rapid clearance. So while DMC’s intrinsic stability advantage is real and repeatedly measured, it has not yet been shown to translate into meaningfully higher plasma or tissue exposure in people ^{1,6Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →Reference 6Chien MH et al. · 2020Dual targeting of the p38 MAPK-HO-1 axis and cIAP1/XIAP by demethoxycurcumin triggers caspase-mediated apoptotic cell death in oral squamous cell carcinoma cellsView study →}.

Clinical Trials

There are no controlled clinical trials of isolated demethoxycurcumin. Human turmeric/curcumin trials use whole rhizome or standardised curcuminoid extracts in which DMC is a minor (~15–20%) component, so their results belong to the mixture, not to DMC specifically.

Last checked: July 2026.

Isolate vs. Plant Studies

DMC sits in an unusual spot. Its mechanistic evidence is genuinely isolate-based — the glioma, oral-cancer, NF-κB, antioxidant and anti-amyloid studies all test purified DMC, often precisely to compare it against curcumin and BDMC ^{2,3,5,7,8Reference 2Sandur SK et al. · 2007Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanismView study →Reference 3Ahsan H et al. · 1999Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcuminView study →Reference 5Kim DS et al. · 2001AnimalCurcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insultView study →Reference 7Lal N et al. · 2018Proteasome mediated degradation of CDC25C and Cyclin B1 in demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrestView study →Reference 8Kumar R et al. · 2018Demethoxycurcumin mediated targeting of MnSOD leading to activation of apoptotic pathway and inhibition of Akt/NF-κB survival signalling in human glioma U87 MG cellsView study →}. That is a strength: we know what the isolated molecule does in a dish.

The human side is entirely plant/extract, and not even DMC-specific: people ingest DMC only inside dietary turmeric or a standardised curcuminoid extract (~95% total curcuminoids), where curcumin dominates. No human study isolates DMC’s contribution. So the correct framing is: solid isolate mechanism + zero isolate human data + a large but curcumin-weighted whole-extract clinical literature that cannot be reassigned to DMC.

Prevalence in Nature

Demethoxycurcumin is essentially confined to turmeric and a handful of related Curcuma species — it is not one of the widely distributed plant metabolites. Within Curcuma longa it is the second curcuminoid, making up roughly 15–20% of the curcuminoid fraction, with curcumin at ~77% and bisdemethoxycurcumin at ~3% ^{1Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →}. The curcuminoid fraction itself is only about 2–9% of the dried rhizome, and its exact composition varies with cultivar, provenance and season, so absolute DMC content in any given turmeric is modest and variable ^{1Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →}. The molecule co-occurs with curcumin, bisdemethoxycurcumin and turmeric’s essential-oil sesquiterpenes such as ar-turmerone.

Discovery & Synthesis

Demethoxycurcumin was identified as one of the three natural curcuminoids of Curcuma longa — the “second curcuminoid” — during the chemical characterisation of turmeric’s pigment fraction that resolved curcumin, demethoxycurcumin and bisdemethoxycurcumin as distinct diarylheptanoids differing only in aromatic-ring methoxylation. It is obtained today the same way it is studied: chromatographic separation from the total curcuminoid extract of turmeric, since the three curcuminoids are co-extracted together and must be resolved to yield pure DMC. Because DMC is asymmetric (one methoxylated ring, one not), targeted total synthesis routes to the pure compound exist for research supply, but commercial material is predominantly isolated from turmeric ^{1Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →}. Its better stability and solubility versus curcumin have made it a recurring scaffold in curcumin-analogue medicinal-chemistry programmes ^{1,6Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →Reference 6Chien MH et al. · 2020Dual targeting of the p38 MAPK-HO-1 axis and cIAP1/XIAP by demethoxycurcumin triggers caspase-mediated apoptotic cell death in oral squamous cell carcinoma cellsView study →}.

Patents: not yet researched.

Toxicity & Safety

DMC carries a low toxicity flag, consistent with the curcuminoid class and with turmeric’s long dietary history. Like curcumin, it shows low toxicity in high-dose and long-term testing, and no isolate-specific toxic syndrome has been described ^{1Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →}. The cautions below are inherited from the curcuminoid class rather than demonstrated uniquely for DMC.

Safety at a Glance

✅ Low / no toxicityBleeding risk

• Low-toxicity curcuminoid. A minor component of a food (turmeric) with a long history of dietary use; no isolate-specific toxicity established ^{1Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →}.
• Antiplatelet / bleeding caution (class-level). Curcuminoids can inhibit platelet aggregation; caution with anticoagulant/antiplatelet drugs and around surgery, extrapolated from the curcumin literature.
• Drug-metabolism interactions (class-level). Curcuminoids modulate CYP enzymes and drug transporters (e.g. P-gp), so interactions with co-administered medicines are plausible; not specifically quantified for DMC.
• Antioxidant/pro-oxidant duality. In the presence of copper, DMC (like curcumin) can switch from antioxidant to DNA-cleaving pro-oxidant in vitro — a reminder that “antioxidant” is context-dependent ^{3Reference 3Ahsan H et al. · 1999Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcuminView study →}.

Reproductive and developmental toxicity has not been characterised for isolated DMC; pregnancy and lactation decisions belong to the turmeric or product page where intake is decided, not to this molecule page.

Dosage

There is no established or recommended human dose for isolated demethoxycurcumin. It is consumed only as one of the three curcuminoids in dietary turmeric or in a standardised curcumin extract (commonly ~95% total curcuminoids), where DMC is roughly a sixth of the curcuminoid content. Cited laboratory concentrations and preclinical doses in the studies above are not convertible to human self-dosing. As with curcumin, any systemic effect is limited by absorption and rapid metabolism; DMC’s greater stability is a structural advantage that has not yet been shown to change practical dosing in people ^{1,6Reference 1Hatamipour M et al. · 2019Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseasesView study →Reference 6Chien MH et al. · 2020Dual targeting of the p38 MAPK-HO-1 axis and cIAP1/XIAP by demethoxycurcumin triggers caspase-mediated apoptotic cell death in oral squamous cell carcinoma cellsView study →}. These are research figures, not a personal recommendation.

References

1. Hatamipour M, Ramezani M, Tabassi SAS, Johnston TP, Sahebkar A (2019). Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseases. Journal of Cellular Physiology. https://pubmed.ncbi.nlm.nih.gov/31344992/
2. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB (2007). Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. https://pubmed.ncbi.nlm.nih.gov/17522064/
3. Ahsan H, Parveen N, Khan NU, Hadi SM (1999). Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chemico-Biological Interactions. https://pubmed.ncbi.nlm.nih.gov/10418962/
4. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP (2007). Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biological & Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.30.74
5. Kim DS, Park SY, Kim JK (2001). Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/11297823/
6. Chien MH, Yang WE, Yang YC, et al. (2020). Dual targeting of the p38 MAPK-HO-1 axis and cIAP1/XIAP by demethoxycurcumin triggers caspase-mediated apoptotic cell death in oral squamous cell carcinoma cells. Cancers (Basel). https://pubmed.ncbi.nlm.nih.gov/32188144/
7. Lal N, Nemaysh V, Luthra PM (2018). Proteasome mediated degradation of CDC25C and Cyclin B1 in demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest. Toxicology and Applied Pharmacology. https://pubmed.ncbi.nlm.nih.gov/30009775/
8. Kumar R, Lal N, Nemaysh V, Luthra PM (2018). Demethoxycurcumin mediated targeting of MnSOD leading to activation of apoptotic pathway and inhibition of Akt/NF-κB survival signalling in human glioma U87 MG cells. Toxicology and Applied Pharmacology. https://pubmed.ncbi.nlm.nih.gov/29510157/

View all 8 references▾